• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 64Resource use associated with drug administration and monitoring

DrugsAdministrationMonitoring
Vials per visitDosesOutpatient visitInfusion costFBCESRLFTU&EChest radiographTB Heaf testANAdsDNA
0–3 months
Etanercept1261022221111
Adalimumab16.51022221111
Infliximab (four vials)a430322221111
Infliximab (three vials)b330322221111
3–6 months
Etanercept126100.50.50.50.50000
Adalimumab16.5100.50.50.50.50000
Infliximab (four vials)a41.62501.6250.50.50.50.50000
Infliximab (three vials)b31.62501.6250.50.50.50.50000
6 months + (3-monthly)
Etanercept1260.500.50.50.50.50000
Adalimumab16.50.500.50.50.50.50000
Infliximab (four vials)a41.62501.6250.50.50.50.50000
Infliximab (three vials)b31.62501.6250.50.50.50.50000
a

Assuming no vial sharing, 5 mg/kg and patient weight of 70–80 kg.

b

Assuming no vial sharing, 5 mg/kg and patient weight of 60 kg.

Assuming no vial sharing, 5 mg/kg and patient weight of 70–80 kg.

Assuming no vial sharing, 5 mg/kg and patient weight of 60 kg.

From: Appendix 13, Costs used in the York model

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.